UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 106

Sortiert nach

Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis

The European respiratory journal, 2011-07, Vol.38 (1), p.59-69

2011

Volltextzugriff (PDF)

Juxtapapillary retinochoroidal coloboma presenting with macular retinoschisis

Indian journal of ophthalmology, 2022-07, Vol.70 (7), p.2770-2770

2022

Volltextzugriff (PDF)

Choroidal flame

Indian journal of ophthalmology, 2022-06, Vol.70 (6), p.1882-1882

2022

Volltextzugriff (PDF)

Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial

The Lancet (British edition), 2008-08, Vol.372 (9640), p.719-727

2008

Volltextzugriff (PDF)

Changes in confocal microscopy in glaucoma patients after intraocular pressure reduction with medical therapy

Indian journal of ophthalmology, 2024-06, Vol.72 (6), p.881-884

2024

Volltextzugriff (PDF)

Circulating tumor DNA as a novel tool to shape clinical trial designs with the potential to impact outcomes: a focus on PI3K inhibitors

Annals of oncology, 2017-11, Vol.28 (11), p.2882-2887

2017

Volltextzugriff (PDF)

Discovery and development of novel therapies in advanced breast cancer: rapid development of ribociclib

Annals of oncology, 2017-08, Vol.28 (8), p.2021-2024

2017

Volltextzugriff (PDF)

Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

The New England journal of medicine, 2019-05, Vol.380 (20), p.1929-1940

2019

Volltextzugriff (PDF)

Extensive myelinated nerve fibers in eye with colobomatous optic disk

Indian journal of ophthalmology, 2020-10, Vol.68 (10), p.2264-2264

2020

Volltextzugriff (PDF)

PI3K inhibitors as new cancer therapeutics: implications for clinical trial design

OncoTargets and therapy, 2016-01, Vol.9 (Issue 1), p.203-210

2016

Volltextzugriff (PDF)

Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Results of the phase III SOLAR-1 trial

Annals of oncology, 2018-10, Vol.29, p.viii709-viii709

2018

Volltextzugriff (PDF)

Quantitative cough assessment in cystic fibrosis (CF)

Journal of cystic fibrosis, 2008-06, Vol.7, p.S59-S59

2008

Volltextzugriff (PDF)

G.P.3.05 Phase 2 study of PTC124 for nonsense mutation suppression therapy of Duchenne muscular dystrophy (DMD)

Neuromuscular disorders : NMD, 2007, Vol.17 (9), p.783-783

2007

Volltextzugriff (PDF)

PTC124 induces CFTR full-length production and activity in children with nonsense-mutation-mediated CF

Journal of cystic fibrosis, 2008-06, Vol.7, p.S22-S22

2008

Volltextzugriff (PDF)

PTC124 treatment over 3 months improves pharmacodynamic and clinical parameters in patients with nonsense-mutation-mediated CF

Journal of cystic fibrosis, 2008-06, Vol.7, p.S22-S22

2008

Volltextzugriff (PDF)

Abstract P4-22-16: First-line ribociclib + letrozole in patients with HR+, HER2– advanced breast cancer (ABC) presenting with visceral metastases or bone-only disease: A subgroup analysis of the MONALEESA-2 trial

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P4-P4-22-16

2017

Volltextzugriff (PDF)

Abstract P4-22-18: Phase Ib safety, efficacy, and molecular analysis of ribociclib (LEE011) plus letrozole for the treatment of ER+, HER2– advanced breast cancer

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P4-P4-22-18

2017

Volltextzugriff (PDF)

Abstract GS2-05: First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trial

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.GS2-05-GS2-05

2018

Volltextzugriff (PDF)

41 PTC124 activity in CF patients carrying stop mutations: results of a phase 2 study

Journal of cystic fibrosis, 2007, Vol.6, p.S10-S10

2007

Volltextzugriff (PDF)

Abstract P4-14-25: Single agent and combined targeting of PI3K, mTOR, HER2 and ER signaling in a panel of HER2+/ER+ versus HER2+/ER- breast cancer cell lines

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P4-P4-14-25

2016

Volltextzugriff (PDF)

Abstract OT2-3-08: Phase III randomized study of the oral pan-PI3K inhibitor BKM120 with fulvestrant in postmenopausal women with HR+/HER2– locally advanced or metastatic breast cancer, treated with aromatase inhibitor, and progressed on or after mTOR inhibitor-based treatment – BELLE-3

Cancer research (Chicago, Ill.), 2012-12, Vol.72 (24_Supplement), p.OT2-3-08-OT2-3-08

2012

Volltextzugriff (PDF)

Abstract P4-22-05: First-line ribociclib plus letrozole in patients with de novo HR+, HER2– advanced breast cancer (ABC): A subgroup analysis of the MONALEESA-2 trial

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P4-P4-22-05

2017

Volltextzugriff (PDF)

Circulating tumor DNA as a novel tool to shape clinical trial designs with the potential to impact outcomes: a focus on PI3K inhibitors

Annals of oncology, 2017-11, Vol.28 (11), p.2882

2017

Volltextzugriff (PDF)

Abstract PD1-5: Targeting PI3K overcomes in vivo resistance to everolimus in estrogen receptor (ER+) breast cancer

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.PD1-5-PD1-5

2013

Volltextzugriff (PDF)

Abstract P4-08-01: PI3K/mTOR inhibition overcomes in vitro and in vivo trastuzumab resistance independent of feedback activation of pAKT

Cancer research (Chicago, Ill.), 2012-12, Vol.72 (24_Supplement), p.P4-P4-08-01

2012

Volltextzugriff (PDF)

1 – 25 von 106

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(105)
Mit Volltextzugriff
(102)

Publikationsform

Artikel
(105)
Dissertationen
(1)

Sprache

Englisch
(106)
Japanisch
(12)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis

Juxtapapillary retinochoroidal coloboma presenting with macular retinoschisis

Choroidal flame

Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial

Changes in confocal microscopy in glaucoma patients after intraocular pressure reduction with medical therapy

Circulating tumor DNA as a novel tool to shape clinical trial designs with the potential to impact outcomes: a focus on PI3K inhibitors

Discovery and development of novel therapies in advanced breast cancer: rapid development of ribociclib

Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

Extensive myelinated nerve fibers in eye with colobomatous optic disk

PI3K inhibitors as new cancer therapeutics: implications for clinical trial design

Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Results of the phase III SOLAR-1 trial

Quantitative cough assessment in cystic fibrosis (CF)

G.P.3.05 Phase 2 study of PTC124 for nonsense mutation suppression therapy of Duchenne muscular dystrophy (DMD)

PTC124 induces CFTR full-length production and activity in children with nonsense-mutation-mediated CF

PTC124 treatment over 3 months improves pharmacodynamic and clinical parameters in patients with nonsense-mutation-mediated CF

Abstract P4-22-16: First-line ribociclib + letrozole in patients with HR+, HER2– advanced breast cancer (ABC) presenting with visceral metastases or bone-only disease: A subgroup analysis of the MONALEESA-2 trial

Abstract P4-22-18: Phase Ib safety, efficacy, and molecular analysis of ribociclib (LEE011) plus letrozole for the treatment of ER+, HER2– advanced breast cancer

Abstract GS2-05: First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trial

41 PTC124 activity in CF patients carrying stop mutations: results of a phase 2 study

Abstract P4-14-25: Single agent and combined targeting of PI3K, mTOR, HER2 and ER signaling in a panel of HER2+/ER+ versus HER2+/ER- breast cancer cell lines

Abstract OT2-3-08: Phase III randomized study of the oral pan-PI3K inhibitor BKM120 with fulvestrant in postmenopausal women with HR+/HER2– locally advanced or metastatic breast cancer, treated with aromatase inhibitor, and progressed on or after mTOR inhibitor-based treatment – BELLE-3

Abstract P4-22-05: First-line ribociclib plus letrozole in patients with de novo HR+, HER2– advanced breast cancer (ABC): A subgroup analysis of the MONALEESA-2 trial

Circulating tumor DNA as a novel tool to shape clinical trial designs with the potential to impact outcomes: a focus on PI3K inhibitors

Abstract PD1-5: Targeting PI3K overcomes in vivo resistance to everolimus in estrogen receptor (ER+) breast cancer

Abstract P4-08-01: PI3K/mTOR inhibition overcomes in vitro and in vivo trastuzumab resistance independent of feedback activation of pAKT

Suchergebnisse filtern